Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of NursingAnswers.net.
Shoulder pain is a common debilitating condition with an estimated annual prevalence ranging from 4.7-46.7%.1 In 2008, nearly 19 million adults (>8% of the US adult population) reported chronic shoulder pain.2 Rotator cuff disorders and glenohumeral osteoarthritis are two of the most common etiologies.3 Patients frequently continue to suffer with pain despite treatment, with 40-50% having continuous or recurrent pain complaints at one year.4,5 Direct costs in 2000 for treating shoulder pain in the United States totaled $7 billion.3
Early in the clinical course of shoulder disorders typical treatments offered include activity modification, physical therapy, oral anti-inflammatories and corticosteroid injections. The long term use of corticosteroid is becoming increasingly controversial, as there are concerns regarding tendon and chondral toxicity.6,7 Until recently, the next step in treatment was often surgical with rotator cuff repair or shoulder arthroplasty. Not all patients are candidates for repair secondary to a variety of patient and lesion factors, and post-operative recovery for arthroplasty has significant down-time.8,9 Newer injection options such as platelet rich plasma and mesenchymal signaling cells (MSCs), the latter of which are typically obtained from autologous bone marrow or adipose tissue are now being increasingly used.10
MSCs are cells with the perceived capability to differentiate into cells that regenerate tissue functionality following injury.11 Numerous mechanisms have been proposed to explain how MSCs may support tissue repair and relieve pain. Secretion of cytokines and growth factors through a paracrine mechanism likely plays a large role.12,13 This paracrine activity is thought to stimulate angiogenesis and have anti-inflammatory properties.14 Secondary to its abundant vasculature, adipose is an excellent medium for MSC harvest. The procurement procedure consists of a minimally invasive harvest with higher cell concentration per unit volume compared to bone marrow concentrate.15 Complex regulations limit utility of culture expansion techniques and enzymatic digestion to obtain stromal vascular fraction. Mechanical treatment with micro-fragmentation provides an effective means of obtaining minimally manipulated adipose tissue known as micro-fragmented adipose tissue (MFAT) for therapeutic use.16
Limited literature is available on the outcomes of patients treated with MFAT for shoulder pain. Continued clinical use necessitates continued analysis of outcomes of the procedure. In the present study, we report the functional and pain outcomes of 15 patients treated with MFAT injections for glenohumeral osteoarthritis and rotator cuff tears.
All patients with glenohumeral osteoarthritis or rotator cuff tears treated with adipose-derived stromal cells from November 2017 to February 2019 at a single outpatient sports medicine clinic were evaluated for inclusion. Diagnosis was obtained through history, examination, and imaging.
Inclusion criteria were: (1) primary diagnosis of glenohumeral osteoarthritis or rotator cuff tear, (2) pathology present on magnetic resonance imaging or plain radiography, (3) pain duration greater than 6 months, and (4) failed conservative management with any combination of physical therapy, corticosteroid injection, visco-supplementation, platelet rich plasma, or arthroscopy. Exclusion criteria were corticosteroid injection within 3 months of MFAT procedure, malignancy, active infection, or auto-immune arthritis.
Fourteen patients (15 shoulders) met criteria and were analyzed. Fourteen shoulders had pathology confirmed through MRI, and in one severe glenohumeral osteoarthritis was confirmed with plain radiography.
The Lipogems® procedural kit was used in all patients. This kit provides the necessary resources for the harvest, processing, and transfer of MFAT. Mild mechanical forces are employed to reduce adipose tissue cluster size and eliminate proinflammatory oil and blood residues.17 The resultant product is neither enzymatically treated nor culture expanded. All injections were performed by two experienced physiatrists using ultrasound guidance (CE, JBS). The following standardized procedural protocol was used:
Harvest site was determined in the standing position. The patient was subsequently placed supine or prone for flank and thigh harvest sites, respectively, and the skin overlying the harvest site was cleansed with chlorhexidine. After injection of local anesthetic, an 18-gauge needle tip was used to create a small incision. The site was infiltrated with tumescent anesthesia (500mL Normal Saline, 1mL of 1:1000 Epinephrine, 50mL of 1% Lidocaine/25mL of 2% Lidocaine, 5mL of 8.4% Sodium Bicarbonate) using the 17-gauge Lipogems® blunt anesthesia tip connected to a 60mL syringe. The cannula was advanced laterally to medially to disperse the tumescent anesthesia. At least 20 minutes post completion of tumescent anesthesia, the lipoaspiration was started.
Fat was harvested using a 13-gauge lipoaspirate cannula connected to a 20mL VacLok syringe. Care was taken to avoid any air being introduced to the syringe. The lipoaspirate syringes were placed in a sterile cup to decant and subsequently transferred to the Lipogems® device for processing. The final product was placed in 3mL syringes for the treatment. As the lipoaspirate was being washing, excess tumescent was expressed from the harvest site and the puncture site was dressed in steri-strips and a sterile gauze, which was then covered by Tegaderm. Tape or mild compression was placed along the harvest site to minimize swelling, bruising, and post-procedure pain.
Ultrasound guidance generally with a curvilinear probe for the glenohumeral joint and linear probe for rotator cuff lesions was used for tissue transfer with an in-plane needle approach. Under sterile conditions, the final adipose aspirate was injected into the target site using a 18g 3.5-inch needle. Average MFAT injectate volume was 5.1 ± 1.5mL for GH arthritis and 1.4 ± 0.6mL for RTC disease. After completion of the procedure, the patient was monitored for 15-20 minutes and provided the post-procedure instructions, which were reviewed in-person.
Approval was obtained from our institution’s quality improvement advisory board; IRB approval was thereby waived by the institution. Data was collected during routine clinic follow-up visits. All patients presented for their 6-month follow-up, with most having additional visits before and after. The following outcomes were collected: visual analog scale (VAS), pain disability index (PDI), and percent global improvement.
The VAS is an 11-point scale with 0 being no pain and 10 being worst possible pain. The PDI is comprised of 7 questions assessing the impact of chronic pain on activities such as recreation, self-care, and occupation. Scores range from 0 (no disability from pain) to 70 (worst disability from pain).18 Percent global improvement scores ranged from 0% (no improvement) to 100% (maximum possible improvement).
Descriptive statistics were used to evaluate variable frequencies. Within participant changes were evaluated using paired two-tailed Student’s t-tests to calculate differences between baseline and 6-month VAS and PDI scores. Mean and standard deviations or percentages are reported for the full cohort. Threshold of significance was set at P < 0.05. A minimal clinically important difference (MCID) value of 1.4-point change was used for VAS and 9.5-point change for PDI.19,20 Descriptive values of proportion of participants meeting MCID are presented.
Demographics and clinical characteristics are depicted in Table 1. Most patients (73%) procedure was in the shoulder of the dominant arm and on average duration of symptoms approached 6 years. Follow-up was obtained in all participants for minimum of 6 months (average follow-up was 9.6 ± 3.9 months). Diagnostic imaging identified severe glenohumeral joint osteoarthritis and partial supraspinatus tears as the most prevalent pathologies, seen in 60% and 40% of patients, respectively (Table 2).
At baseline, mean VAS was 6.5 ± 2.1 and mean PDI was 20.7 ± 10.3. There was significant improvement between baseline and 6-month follow up VAS (p < 0.001) and PDI (p =0.03) (Figure 1 and 2). At 6 months, the MCID was met for 87% of patients for VAS and 47% of patients for PDI. Paired comparison at 2 months and >8 months was unable to be completed as not all patients attended these follow-up visits. At final follow-up, global improvement averaged 70% (range 20-100%). One minor complication was reported of transient contact dermatitis from the dressing applied to the harvest site. No other complications were observed or reported.
Table 1: Demographic and Clinical Characteristics
Table 2: Patient Pathology
Figure 1: VAS Score Changes
Figure 2: PDI Score Changes
Recalcitrant shoulder pain from osteoarthritis and rotator cuff pathology remains a common problem encountered in clinical practice. In this population of 15 patients, a majority reported significant improvements in pain and/or disability at six months using MCID criteria and no major adverse events were reported. These findings are notable as all patients had failed multiple prior conservative interventions, were not candidates or not ready for surgery, and reported pain and functional limitations for many months. The findings suggest MFAT may be successful in a portion of patients with shoulder pain from GHJ arthritis or RTC disease, with benefits measured 6 months from procedure.
Current literature on MFAT use for shoulder pain remains limited. A case report of a T10 complete paraplegic wheelchair user with chronic shoulder pain found improved pain and functional outcomes one-year post Lipogems® procedure.21 The patient was able to maintain functional independence and resume activities of daily living; demonstrating promising results of MFAT for shoulder pain in a challenging population for which shoulder surgery limits functional independence. Striano et al. reported results on 18 patients with chronic shoulder pain treated with MFAT.22 Patients were followed for one year and significant improvement was noted for pain reduction and functional improvement using the Numeric Pain Scale and American Shoulder and Elbow Surgeons Score. Pain scores decreased from a baseline of 7.5 to 3.6 at one year. In the present study, we observed similar improvement in pain and disability. While statistical analyses could not be completed for after 6 months in our study, seven patients had follow-up times greater than 10 months with average point decreases of 4.2 and 4.6 in VAS and PDI, respectively, from baseline.
Two studies report stromal vascular fraction (SVF) outcomes on shoulder pain via arthroscopy. Jo et al treated 19 patients with varying doses of culture expanded SVF at the time of an arthroscopic examination.23 Significant improvement was found at six months for the mid and high dose groups. The SVF used in this study was obtained through enzymatic digestion. Notably, culture-expanded cells are not approved for use in the United States as they violate the Federal Drug Administration’s minimal manipulation regulations for MSCs. Kim et al compared outcomes of surgical repair alone for rotator cuff tears against repair coupled with injection of adipose-derived MSCs loaded in fibrin glue. They found decreased re-tear rates in the surgery plus adipose-derived MSC group, but no significant differences in pain outcomes.24 These studies demonstrate positive early evidence for combined SVF and surgical intervention. Notably, SVF differs from MFAT and more evidence is needed to ascertain comparative efficacy.
Multiple mechanisms have been proposed for how adipose-derived signaling cells may improve pain and function for shoulder pathology. Immunomodulatory and anti-inflammatory properties secondary to a paracrine secretion of growth factors and cytokines likely contributes.12 Additionally, tendon needling when treating rotator cuff tears invariably occurs and can have pain relieving properties.25 Animal model studies have demonstrated decreased fatty infiltration of rotator cuff tears after adipose-derived MSC treatment.26,27Fatty infiltration is often associated with a reduction in tissue regenerative potential, limiting it may play a role in adipose-derived MSCs therapeutic effect.28
While the findings are encouraging, results of this large case series should be interpreted with caution. Case series retrospective design is limited by sample size and absence of control group. Selection bias of participants may influence results (including choice of procedure and out of pocket expense). The degree of osteoarthritis and rotator cuff tear severity may also influence results and was not controlled for in this study. Additionally, subgroup analysis of GHJ osteoarthritis versus rotator cuff tear was unable to be performed due to the small sample size. Follow-up was obtained for a subset of patients to 6 months, and clinical results are often reported at time points 12 months after the procedure.29,30 However, this report adds to the limited literature using Lipogems® and suggests further investigations using rigorous methodology (randomization, blinding, and larger sample sizes with more homogenous degree of pathology) would help understand the benefits of this procedure.
Our results suggest MFAT may be helpful to improve pain and function in a subset of patients with chronic glenohumeral osteoarthritis and rotator cuff tears. No major complications were identified in our case series. Additional studies ideally prospective with a control group are needed for further evaluation of this treatment.
Table 1: Demographic and Clinical Characteristics
Values are mean and standard deviation or percentages. BMI – body mass index, PRP – platelet rich plasma, MRI – magnetic resonance imaging
Table 2: Patient Pathology
Values are percentages.
Figure 1: VAS Score Changes
VAS – Visual Analog Scale
Figure 2: PDI Score Changes
1. Luime JJ, Koes BW, Hendriksen IJM, et al. Prevalence and incidence of shoulder pain in the general population; a systematic review. Scand J Rheumatol. 2004;33(2):73-81. doi:10.1080/03009740310004667
2. Black EM, Higgins LD, Warner JJP. Value-based shoulder surgery: Practicing outcomes-driven, cost-conscious care. J Shoulder Elb Surg. 2013;22(7):1000-1009. doi:10.1016/j.jse.2013.02.008
3. Meislin RJ, Sperling JW, Stitik TP. Persistent shoulder pain: epidemiology, pathophysiology, and diagnosis. Am J Orthop (Belle Mead NJ). 2005;34(12 Suppl):5-9. http://www.ncbi.nlm.nih.gov/pubmed/16450690. Accessed September 7, 2019.
4. W M Van Der Windt Bart W Koes A Joan P Boeke Walter Deville Bareld A De Jong Lex M Bouter DA, Joan Boeke AP, investigator senior, Bouter LM. Shoulder disorders in general practice: prognostic indicators of outcome assistant professor in epidemiology and. C Br Joumal Gen Pract. 1996;46(October):519-523. http://pubmedcentralcanada.ca/pmcc/articles/PMC1239746/pdf/brjgenprac00004-0023.pdf. Accessed September 7, 2019.
5. Cadogan A, Laslett M, Hing WA, McNair PJ, Coates MH. A prospective study of shoulder pain in primary care: Prevalence of imaged pathology and response to guided diagnostic blocks. BMC Musculoskelet Disord. 2011;12. doi:10.1186/1471-2474-12-119
6. Dean BJF, Lostis E, Oakley T, Rombach I, Morrey ME, Carr AJ. The risks and benefits of glucocorticoid treatment for tendinopathy: A systematic review of the effects of local glucocorticoid on tendon. Semin Arthritis Rheum. 2014;43(4):570-576. doi:10.1016/j.semarthrit.2013.08.006
7. Sherman SL, Khazai RS, James CH, Stoker AM, Flood DL, Cook JL. In vitro toxicity of local anesthetics and corticosteroids on chondrocyte and synoviocyte viability and metabolism. Cartilage. 2015;6(4):233-240. doi:10.1177/1947603515594453
8. Petrillo S, Longo UG, Papalia R, Denaro V. Reverse shoulder arthroplasty for massive irreparable rotator cuff tears and cuff tear arthropathy: a systematic review. Musculoskelet Surg. 2017;101(2):105-112. doi:10.1007/s12306-017-0474-z
9. Wilcox RB, Arslanian LE, Millett P. Rehabilitation following total shoulder arthroplasty. J Orthop Sports Phys Ther. 2005;35(12):821-836. doi:10.2519/jospt.2005.35.12.821
10. Borg-Stein J, Osoria HL, Hayano T. Regenerative Sports Medicine: Past, Present, and Future (Adapted From the PASSOR Legacy Award Presentation; AAPMR; October 2016). PM R. 2018;10(10):1083-1105. doi:10.1016/j.pmrj.2018.07.003
11. DeChellis DM, Cortazzo MH. Regenerative medicine in the field of pain medicine: Prolotherapy, platelet-rich plasma therapy, and stem cell therapy-Theory and evidence. Tech Reg Anesth Pain Manag. 2011;15(2):74-80. doi:10.1053/j.trap.2011.05.002
12. Freitag J, Bates D, Boyd R, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: Reparative pathways, safety and efficacy – A review. BMC Musculoskelet Disord. 2016;17(1). doi:10.1186/s12891-016-1085-9
13. Djouad F, Bouffi C, Ghannam S, Noël D, Jorgensen C. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5(7):392-399. doi:10.1038/nrrheum.2009.104
14. Hudetz D, Borić I, Rod E, et al. Early results of intra-articular micro-fragmented lipoaspirate treatment in patients with late stages knee osteoarthritis: a prospective study. Croat Med J. 2019;60(3):227-236. doi:10.3325/cmj.2019.60.227
15. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012;21(14):2724-2752. doi:10.1089/scd.2011.0722
16. Bianchi F, Maioli M, Leonardi E, et al. A new nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates. Cell Transplant. 2013;22(11):2063-2077. doi:10.3727/096368912X657855
17. Tremolada C, Colombo V, Ventura C. Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development. Curr Stem Cell Reports. 2016;2(3):304-312. doi:10.1007/s40778-016-0053-5
18. Jerome A, Gross RT. Pain disability index: construct and discriminant validity. Arch Phys Med Rehabil. 1991;72(11):920-922. doi:10.1016/0003-9993(91)90012-8
19. Tashjian RZ, Deloach J, Porucznik CA, Powell AP. Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease. J Shoulder Elb Surg. 2009;18(6):927-932. doi:10.1016/j.jse.2009.03.021
20. Soer R, Reneman MF, Vroomen PCAJ, Stegeman P, Coppes MH. Responsiveness and minimal clinically important change of the pain disability index in patients with chronic back pain. Spine (Phila Pa 1976). 2012;37(8):711-715. doi:10.1097/BRS.0b013e31822c8a7a
21. Cherian C, Malanga GA, Hogaboom N, Pollack MA, Dyson-Hudson TA. Autologous, micro-fragmented adipose tissue as a treatment for chronic shoulder pain in a wheelchair using individual with spinal cord injury: a case report. Spinal Cord Ser Cases. 2019;5(1). doi:10.1038/s41394-019-0186-8
22. RD Striano GMNBKA. Refractory shoulder pain with osteoarthritis, and rotator cuff tear, treated with micro fragmented adipose tissue. Orthop Spine Sport Med. 2018;2:014.
23. Jo CH, Chai JW, Jeong EC, et al. Intratendinous Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Rotator Cuff Disease: A First-In-Human Trial. Stem Cells. 2018;36(9):1441-1450. doi:10.1002/stem.2855
24. Kim YS, Sung CH, Chung SH, Kwak SJ, Koh YG. Does an Injection of Adipose-Derived Mesenchymal Stem Cells Loaded in Fibrin Glue Influence Rotator Cuff Repair Outcomes? A Clinical and Magnetic Resonance Imaging Study. Am J Sports Med. 2017;45(9):2010-2018. doi:10.1177/0363546517702863
25. Krey D, Borchers J, McCamey K. Tendon needling for treatment of tendinopathy: A systematic review. Phys Sportsmed. 2015;43(1):80-86. doi:10.1080/00913847.2015.1004296
26. Eliasberg CD, Dar A, Jensen AR, et al. Perivascular stem cells diminish muscle atrophy following massive rotator cuff tears in a small animal model. J Bone Jt Surg – Am Vol. 2017;99(4):331-341. doi:10.2106/JBJS.16.00645
27. Oh JH, Chung SW, Kim SH, Chung JY, Kim JY. 2013 Neer Award: Effect of the adipose-derived stem cell for the improvement of fatty degeneration and rotator cuff healing in rabbit model. J shoulder Elb Surg. 2014;23(4):445-455. doi:10.1016/j.jse.2013.07.054
28. Osti L, Buda M, Del Buono A. Fatty infiltration of the shoulder: diagnosis and reversibility. Muscles Ligaments Tendons J. 2013;3(4):351-354. http://www.ncbi.nlm.nih.gov/pubmed/24596701. Accessed October 3, 2019.
29. Jo CH, Chai JW, Jeong EC, et al. Intra-articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee: A 2-Year Follow-up Study. Am J Sports Med. 2017;45(12):2774-2783. doi:10.1177/0363546517716641
30. Cattaneo G, De Caro A, Napoli F, Chiapale D, Trada P, Camera A. Micro-fragmented adipose tissue injection associated with arthroscopic procedures in patients with symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2018;19(1):176. doi:10.1186/s12891-018-2105-8
Cite This Work
To export a reference to this article please select a referencing stye below:
Related ServicesView all
DMCA / Removal Request
If you are the original writer of this dissertation and no longer wish to have your work published on the UKDiss.com website then please: